secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2026-06-26T20:30:19+00:00
Accession:  0001493152-26-030306
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SVP of Finance Sandra Gurrola resigns, effective July 3, 2026
-------------------------------------------------------------

- Sandra Gurrola, SVP of Finance, resigned June 22, 2026, effective July 3, 2026.
- Resignation not due to any disagreement with the Company's operations, policies, or practices.
- Gurrola will provide part-time transition assistance (up to 10 hrs/week) through Q2 2026 10-Q filing.
- Company has initiated search for a successor and will use outside support for finance, accounting, and reporting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000149315226030306/0001493152-26-030306-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000149315226030306/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-030306

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer